Topadur Pharma

Zurich-Schlieren, Switzerland, 2 November 2023

We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.

‍

Download Document Dokument herunterladen

19.5.22

Press Release

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.

5.1.24

Press Release

Topadur Pharma AG receives an innosuisse grant

CHF 1.76 million is awarded from Innosuisse for the Phase 2a clinical trial with TOP-N53 in the treatment of digital ulcers

8.9.22

News

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Topadur Pharma AG receives an innosuisse grant

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

Contact

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Topadur Pharma AG receives an innosuisse grant

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

About us

Approach

Disease Areas

Investors

Contact